Evaluation of a new PT-INR monitoring system in patients with the antiphospholipid syndrome
Summary Introduction Patients on anticoagulant therapy with vitamin K antagonists (VKA) need frequent INR monitoring. Reliability of point‐of‐care (POC) devices for measuring INR needs rigorous evaluation, particularly in patient with the antiphospholipid syndrome (APS). The aim of this study was to...
Saved in:
Published in: | International journal of laboratory hematology Vol. 38; no. 5; pp. 497 - 504 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Blackwell Publishing Ltd
01-10-2016
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Summary
Introduction
Patients on anticoagulant therapy with vitamin K antagonists (VKA) need frequent INR monitoring. Reliability of point‐of‐care (POC) devices for measuring INR needs rigorous evaluation, particularly in patient with the antiphospholipid syndrome (APS). The aim of this study was to evaluate the accuracy of the ProTime InRhythm™ System (here called device) for INR measurement in patients with APS on VKA.
Methods
We compared the device INR vs. the laboratory INR measurement for blood samples from 29 APS‐positive and 31 APS‐negative patients consecutively enrolled. APS was confirmed by positive serological and/or phospholipid‐dependent coagulation tests. Chromogenic factor X assay was used to evaluate anticoagulation. Bland–Altman difference plot for paired INR (POC vs. laboratory) was used to evaluate agreement between the device and the laboratory. The device INR relationship with factor X chromogenic assay was evaluated by orthogonal regression analysis.
Results
Overall, 97% of the device INR measurements were similar to laboratory INR values with an absolute difference less than 0.4 units. Correlation coefficient for the device INR vs. factor X was −0.69 (P < 0.0001, CI 95% −0.80 to −0.52).
Conclusions
The ProTime InRhythm System™ is an accurate point‐of‐care device for measuring INR also in patients with and without APS. |
---|---|
Bibliography: | Accriva Diagnostics istex:C66E7B193DD2DCD59444D06E7E8E1F5BEDAC0263 ark:/67375/WNG-6PGRPQFV-D ArticleID:IJLH12523 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1751-5521 1751-553X |
DOI: | 10.1111/ijlh.12523 |